21 October 2025 in Epilepsia
Objective: Accumulating evidence indicates that aberrant C1q‐C3 complement signaling in microglia and astrocytes drives synaptic dysfunction and neuronal loss. C1q‐mediated synaptic dysfunction disrupts neuronal circuitry balance and can lead to network hyperexcitability in epilepsy. However, the therapeutic potential of C1q inhibition remains unclear. This study aimed to delineate whether blocking C1q‐driven pathways at critical times can effectively prevent further synaptic loss and attenuate epileptiform activity in a mouse model of epilepsy. Methods: Microglial C1q and astrocytic C3 expression was examined in hippocampal CA1 and CA3 regions at acute (1 day), subacute (7, 14 days), and chronic (5 weeks) phases following pilocarpine‐induced status epilepticus (SE) in mice. To evaluate the role of C1q activation, a C1q‐neutralizing antibody or isotype control immunoglobulin G antibody was administered into cisterna magna at 7 days post‐SE. During the chronic phase, glial reactivity, dendritic spine density, and epileptiform activity were assessed by immunostaining, Golgi staining, and electroencephalography (EEG) recording. After exclusions, 58 mice were included in the study. Results: C1q expression was elevated during the subacute phase (7 and 14 days post‐SE) in CA1 and CA3 regions; astrocytic C3 expression increased in CA1 and persisted chronically. C1q‐neutralizing antibody administration at 7 days post‐SE, a time point characterized by prominent C1q upregulation, attenuated microglial synaptic phagocytosis, and astrocytic C3 activation. This intervention preserved dendritic spine density and ultimately reduced interictal spike frequency in EEG recordings in the chronic phase. Significance: Our findings demonstrate that C1q acts as an upstream mediator of complement‐driven neuronal loss during epileptogenesis. C1q blockade interrupted the pathogenic cascade involving microglial engulfment and astrocytic C3 upregulation, thereby preserving synaptic and neuronal integrity and reducing interictal spike activity. Our study highlights the therapeutic potential of C1q inhibition, which can provide multifaceted benefits by mitigating neuroinflammation, improving synaptic integrity, and reducing epileptiform activity during epileptogenesis.
28 July 2025 in Signal Transduction and Targeted Therapy
Post-traumatic stress disorder (PTSD) remains a debilitating psychiatric condition with limited pharmacological treatment options. Identifying novel therapeutic targets is critical for addressing its unmet clinical needs. Through our comprehensive human clinical research, including both cross-sectional and longitudinal studies, we revealed a compelling link between dysregulated prefrontal gamma-aminobutyric acid (GABA) levels and PTSD symptoms. Notably, elevated prefrontal GABA levels in PTSD patients are associated with impaired cerebral blood flow (CBF) and symptom severity, normalizing with recovery, highlighting GABA dysregulation as a key mechanism in the disorder. Postmortem and PTSD-like mouse models implicated monoamine oxidase B (MAOB)-dependent astrocytic GABA as a primary driver of this imbalance, exacerbating deficit in fear extinction retrieval. Genetic and pharmacological inhibition of MAOB effectively restored astrocytic GABA and improved fear extinction retrieval in PTSD-like mouse models. Specifically, KDS2010, a recently developed highly selective and reversible MAOB inhibitor, not only restored astrocytic GABA homeostasis but also rescued CBF deficits and reduced tonic GABA and astrogliosis in the prefrontal cortex. Moreover, KDS2010 successfully advanced through Phase 1 clinical trials, showing a favorable safety profile and paving the way for Phase 2 trials to evaluate its therapeutic potential in PTSD. Our findings highlight the pivotal role of astrocytic GABA in PTSD pathophysiology and establish MAOB inhibition as a mechanistically targeted approach to alleviate symptoms. By bridging human and animal studies with translational clinical trials, this work positions KDS2010 as a promising first-in-class therapy, offering a novel paradigm for PTSD treatment.
1 October 2025 in Neurophotonics
The blood–brain barrier (BBB) plays a central role in maintaining central nervous system (CNS) homeostasis by tightly regulating the exchange of substances between blood and brain parenchyma.1 – 3 Under physiological conditions, the BBB acts as a selective barrier that prevents circulating neurotoxins and immune cells from infiltrating the brain. Recent studies have indicated that the BBB is not a uniform structure. Instead, it displays heterogeneity across brain regions.4,5 Specifically, this heterogeneity in the BBB composition is highly dependent on the types of blood vessels, i.e., from arteries to capillaries to veins.6,7 Emerging research using single-cell RNA sequencing (scRNA-seq) has revealed distinct transcriptional patterns across arterial, capillary, and venous endothelial cells, indicating that each vascular type possesses unique functional characteristics.8 Under pathological conditions such as Alzheimer’s disease, these transcriptomic differences across vascular types are further amplified, with cell-type-specific dysregulation playing a key role in exacerbating BBB dysfunction.9,10 Given the functional specialization of each vascular segment, such molecular alterations are likely to manifest as vessel-type-specific changes in BBB permeability. This suggests that vascular-type-specific BBB dysfunction might drive heterogeneous permeability alterations during disease progression. Although previous studies have provided valuable molecular insights through gene and protein profiling, these approaches alone are insufficient to characterize the functional integrity of the BBB, particularly its permeability properties, which depend on disease stages. It remains unclear how such molecular profiles translate into actual changes in barrier function across vascular types. Therefore, direct and quantitative assessment of BBB leakage at the single-vessel level is essential for linking molecular alterations to functional outcomes. This approach is not only critical for understanding vessel-specific BBB disruption mechanisms but also essential for evaluating the efficacy of targeted therapeutic strategies in a disease-specific manner.